# A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

> **NCT07735533** · PHASE1,PHASE2 · RECRUITING · sponsor: **Umoja Biopharma** · enrollment: 274 (estimated)

## Conditions studied

- Lymphoma, B Cell
- Lymphoma Non-Hodgkin
- High Grade B Cell Lymphoma
- Richter Transformation Lymphoma
- Grade 3b Follicular Lymphoma
- Primary Mediastinal B Cell Lymphoma
- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **GENETIC:** UB-VV400
- **DRUG:** Rapamycin (sirolimus)

## Key facts

- **NCT ID:** NCT07735533
- **Lead sponsor:** Umoja Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2031-08
- **Final completion:** 2031-08
- **Target enrollment:** 274 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07735533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07735533, "A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07735533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*